


PANCREATIC CANCER

General Overview

- 4th most common cause of cancer death in Europe
- Diagnosed at an advanced stage due to its aggressive biology and non-specific symptoms. Only 5% of PDAC patients survive 10y
- More than half of patients present with M+ disease
- Adenocarcinoma (PDAC) is the most frequent histology type.
- Risk factors: age, tobacco, alcohol, overweight, new onset diabetes, pancreatitis, Helicobacter pylori infection
- Familial pancreatic cancer (4-10%), variants with BRCA2 are the most common pathogenic germline alterations
- Clinical symptoms: weight loss, pain, jaundice
- 5y survival has increased over the last 30y from 4 to 13%
- Will become the 2nd leading cause of cancer related deaths by 2030



Staging (AJCC Version 8) and Prognosis

- CT three-phase (pancreatic, arterial and portal).

Primary Tumor (T)	Regional Lymph Nodes (N)	Distant Metastasis (M)
Tx: Primary tumor cannot be assessed	Nx: LN cannot be assessed	M0: no distant M+
T0: No evidence of primary tumor	N0: no regional LN	M1: distant M+
Tis: Ca in situ, high grade dysplasia	N1: M+ in 1-3 regional LN	
T1: tumor ≤2 cm in greatest dim	N2: M+ in 4 or more reg LN	
T1a: tumor ≤0.5 cm		
T1b: 0.5 < tumor <1 cm		
T1c: tumor 1-2 cm		
T2: 2 < tumor ≤4 cm in greatest dim		
T3: tumor >4 cm in greatest dim		
T4: tumor involves celiac axis, sup mesenteric artery, and/or common hepatic artery (regardless of size)		

Prognostic stage group	TNM	5y survival (%)
IA	T1 N0 M0	39
IB	T2 N0 M0	34
IIA	T3 N0 M0	28
IIB	T1 N1 M0	21
	T2 N1 M0	
III	T1 N2 M0	11
	T2 N2 M0	
	T3 N2 M0	
	T4, any N M0	
IV	Any T any N M1	

References

- 1) Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial. *JAMA*. 2013;310(14):1473–1481. doi:10.1001/jama.2013.279201
- 2) Conroy T, Hammel P, Hebbar M, et al. Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. *N Engl J Med*. 2018;379(25):2395–406.
- 3) Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med*. 2011;364:1817–25. (update Jama oncol 2022 Conroy et al)
- 4) Von Hof DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. *N Engl J Med*. 2013;369:1691–703
- 5) Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA mutated metastatic pancreatic cancer. *N Engl J Med*. 2019;381(4):317–27 (update: JCO 2022 Kindler et al)
- 6) Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet*. 2016;387:545–57.
- 7) T. Conroy, P. Pfeiffer et al Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up *Annals of oncology* 2023
- 8) Kakar S, Pawlik TM, Allen PJ, Vauthey J-N.. Exocrine pancreas. In: *AJCC Cancer Staging Manual*, 8th, Amin MB (Ed), AJCC, Chicago 2017. p.337

What's new ?

- CD40 agonist mitazalimab with mFOLFIRINOX: Van Laethem et al *Lancet oncol* 2024
- Neoantigen T-cell receptor gene therapy in pancreatic cancer *NEJM* June 2022
- Personalize RNA neoantigen vaccines in pancreatic cancer *Nature* June 2023
- Sotorasib in KRAS G12C mutated advanced pancreatic cancer *NEJM* 2023 (Strickler et al)
- NORPACT-1: neoadj FOLFIRINOX vs upfront surgery for resectable pancreatic head cancer
 - *Lancet Gastroenterol Hepatol* 2024; Phase 2 ; Negative study !!
- CAR-T CT041 in refractory metastatic pancreatic cancer *JCO* 2024 Changsong Qi et al
- PANOVA-3 Study (phase 3): Tumor Treating Fields (electric fields) + chemo 1st line *JCO* July 2025 (Babiker et al)
- Chemoradiotherapy in locally advanced / unresectable pancreatic cancer
 - CONKO-007 (*JCO* oct 2025): chemoRT vs chemo after induction therapy for conversion
 - PREOPANC-2 (*Lancet oncol* oct 2025): neoadj FOLFIRINOX vs neoadj chemoRT (+gem) in resectable and borderline resectable: no diff in OS